Official Sections CTRMS ISVCA IPITA IPTA ISODP IRTA IXA SPLIT TID

2013 - ISBTS 2013 Symposium


This page contains exclusive content for the member of the following sections: TTS, IXA, ITA

Mini-Oral Communications 1

12.253 - Reproductive health and outcomes following intestine transplantation

Presenter: Beverly, Kosmach-Park, , United States
Authors: Beverly Kosmach-Park1, Dolly Martin1, Guillherme Costa2, George Mazariegos1

Reproductive health and outcomes following intestine transplantation

Beverly Kosmach-Park1, Dolly Martin1, Guillherme Costa2, George Mazariegos1

1Transplant Surgery, Children's Hospital of Pittsburgh, Pittsburgh, PA, United States; 2Transplant Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States

Background:  Pregnancy after transplantation has become a reality for female transplant recipients desiring parenthood, particularly after renal or liver transplantation.  Women at 1-2 yrs post-transplant with good graft and kidney function, stable immunosuppression and in overall good health, may consider pregnancy after pre-conception counseling.  With improved long-term survival following intestine transplant (ITx), pediatric recipients are reaching puberty and surviving into reproductive age.  Adult recipients are resuming sexual activity and some are considering parenthood.  
Objective:  Describe reproductive outcomes of ITx recipients.
Methods:  Database, chart review and patient reports were used to describe peripregnancy patient and infant outcomes.
Results:  Three ITx recipients had 4 pregnancies at 3.4-13 yrs post-ITx.  Maternal Outcomes:  Indications for ITx : volvulus (n=2), pseudo-obstruction (n=1).  Women’s ages at ITx= 13.2, 22.2 and 26.9 yrs;  at delivery = 24.3, 26.4, 26.6 and 30.3 yrs.  All women received tacrolimus (TAC), mean levels during  pregnancy ranged from 2.5 to 6.5 ng/ml.  One pt received daily prednisone.  Two pts had 3 previous episodes of ACR, one moderate treated with OKT3;  another had 2 mild episodes treated with steroids.  There were no significant complications that affected maternal outcomes with pts maintaining stable graft and kidney function.  Mean BUN and creatinine levels during pregnancy:  16.1 mg/dL , 1.13 mg/dL.  Mean levels of nutritional markers and graft function:  albumin 3.4 g/dL, protein 6.2 g/dL, magnesium 1.4 mg/dL.  Pts were normotensive; there were no incidences of gestational diabetes.  Polyhydraminos developed in one pregnancy and resolved without incident.  There was fetal exposure to lithium during the first month of pregnancy in one pt being treated for depression and bipolar disorder.  Ultrasounds revealed no structural abnormalities at 25 weeks gestation.  Maternal outcomes were favorable with normal surveillance endoscopies at 1-6 mos post-partum, stable graft function, no rejection and stable TAC levels. One pt reported new onset migraines following the birth of her son.  Infant Outcomes:  3 females and 1 male at 35-39 wks gestation (mean 37.7 wks). Normal fetal growth, activity and development were reported during each pregnancy. Three infants were delivered by Caesarean section (2 emergent, 1 planned).  The infants’ Apgar scores at 1 minute were 5-8 , at 5 minutes was 9 for all.  Birthweights = 2270-3885 grams (mean= 3105 gm).  TAC levels were measured in 3 infants at 24 hrs after birth = 2.4, 3.7 and < 5 ng/ml.  None of the infants were breastfed due to concerns for low levels of TAC in breast milk.  Two infants were hospitalized for additional days after birth, one for temperature instability and the other for poor feeding.  Infant outcomes were excellent with all currently healthy and achieving developmental milestones at 3-7 years of age per maternal report. 
Conclusions: These outcomes suggest that healthy pregnancies are possible following ITx in pts who have stable graft function, good renal function, stable immunosuppression without recent evidence of rejection and general good health.  It is also important that ITx recipients be under the care of a high-risk obstetrician and maintain close follow-up with the transplant center. The ability to conceive and have a successful delivery following ITx  is an important outcome that may contribute to an improved quality of life.


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
This email address is being protected from spambots. You need JavaScript enabled to view it.

Address

The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7
Canada